Now Available: Optune Portable Treatment for Glioblastoma
Optune®, an FDA-approved therapy for the treatment of newly diagnosed and recurrent glioblastoma (GBM), is now available at South Denver Neurosurgery. This portable and wearable device is the first FDA-approved therapy in more than a decade for newly diagnosed GBM.
Optune is approved for the treatment of adult patients (22 years of age or older) with GBM. For newly diagnosed patients, Optune is used with the chemotherapy temozolomide (TMZ) after surgery and radiation with TMZ.
For recurrent patients, it can be used alone when surgery and radiation treatment options have been exhausted. In a clinical trial, adding Optune to TMZ was proven to delay GBM tumor growth and extend survival in newly diagnosed patients compared with TMZ alone.
For more information about this device, go to Optune.com.
Watch a video about Optune® and hear from two patients who are receiving treatment:
Indications for Use
Optune® is intended as a treatment for adult patients (22 years of age or older) with histologicallyconfirmed
glioblastoma multiforme (GBM).
Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed,
supratentorial glioblastoma following maximal debulking surgery and completion of radiation
therapy together with concomitant standard of care chemotherapy.
For the treatment of recurrent GBM, Optune is indicated following histologically–or radiologically–
confirmed recurrence in the supratentorial region of the brain after receiving chemotherapy. The
device is intended to be used as a monotherapy, and is intended as an alternative to standard medical
therapy for GBM after surgical and radiation options have been exhausted.
Important Safety Information
There are contraindications, warnings and precautions about the use of Optune. Please speak to your physician about these, and see complete information on instructions for use on the Optune website.